The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease?

Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations

(2012) Núria Planell et al.   GUT

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Full-Length IL-33 Promotes Inflammation but not Th2 Response In Vivo in an ST2-Independent Fashion

(2012) I. G. Luzina et al.   JOURNAL OF IMMUNOLOGY

RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation

(2012) T Kanai et al.   Mucosal Immunology

Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially Expressed in Ulceration-Associated Myofibroblasts

(2010) Jon Sponheim et al.   AMERICAN JOURNAL OF PATHOLOGY

Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis

(2010) Ayako Kobori et al.   JOURNAL OF GASTROENTEROLOGY

Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis

(2010) Luca Pastorelli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-33 and IL-33 Receptors in Host Defense and Diseases

(2010) Keisuke Oboki et al.   ALLERGOLOGY INTERNATIONAL

IL-33 is upregulated in colonocytes of ulcerative colitis

(2009) Jakob Benedict Seidelin et al.   IMMUNOLOGY LETTERS

Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease

(2009) Caroll J. Beltrán et al.   INFLAMMATORY BOWEL DISEASES

IL-33 Induces IL-13-Dependent Cutaneous Fibrosis

(2009) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY